Knopp Neurosciences Receives Orphan Designation For KNS-760704 For Treatment Of ALS

Knopp Neurosciences Inc. (”Knopp”) announced that the U.S. Food and Drug Administration’s Office of Orphan Products Development has granted orphan drug designation to KNS-760704 for the treatment of amyotrophic lateral sclerosis (ALS). KNS-760704 is now completing Phase 1 studies to evaluate the safety, tolerability and pharmacokinetics of the compound in healthy human subjects. [click link for full article]

More: continued here

Filed under: Muscular Dystrophy on October 20th, 2007